— Know what they know.
Not Investment Advice

MEDP NASDAQ

Medpace Holdings, Inc.
1W: +9.2% 1M: +9.3% 3M: +18.5% YTD: +18.5% 1Y: +13.4% 3Y: +194.8% 5Y: +264.2%
$673.79
-2.98 (-0.44%)
After Hours: $676.25 (+2.46, +0.37%)
Weekly Expected Move ±5.1%
$601 $635 $669 $703 $738
NASDAQ · Healthcare · Medical - Diagnostics & Research · Tech Score Strong Buy · Power 76 · $18.9B mcap · 23M float · 1.34% daily turnover · Short 61% of daily vol
Credit Risk of going bust: lower than 87% of companies Debt: 0.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.51 (down 99.9%), Medpace Holdings, Inc. would be worth roughly what it owes.
Total debt $146.0M against a stock market value of $18.93B.
Distance to default 12.17 (Merton model): prices to 2026-10-26, balance sheet 2026-09-30, debt counted $73.0M (short-term plus half of long-term), stock volatility 45.4%; Altman Z'' 0.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NARROW EDGE
61.5 / 100
NoneWeakNarrowWide
Primary source: Cost Advantage  ·  ROIC: 1953.7%  ·  5Y Avg: 311.0%
Cost Advantage ★
100
Intangibles
19
Switching Cost
60
Network Effect
50
Scale
95
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. MEDP has a Narrow competitive edge (61.5/100) — meaningful but not impregnable advantages over competitors. The primary source of advantage is Cost Advantage. ROIC of 1953.7% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$633
Low
$684
Avg Target
$730
High
Based on 6 analysts since Oct 21, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 4Hold: 15Sell: 0Strong Sell: 0
Rating Summary
ConsensusHold
Avg Target$678.33
Analysts9
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-10-26 BMO Capital — $600 $670 +70 +0.2% $668.97
2026-10-23 Truist Financial Jailendra Singh $539 $633 +94 -3.5% $656.25
2026-10-23 UBS — $673 $700 +27 +5.6% $662.60
2026-10-23 Mizuho Securities — $700 $730 +30 +11.6% $653.96
2026-10-23 Robert W. Baird — $624 $699 +75 +6.9% $653.96
2026-10-23 Barclays — $625 $675 +50 +3.2% $653.96
2026-10-07 Mizuho Securities — $665 $700 +35 +16.1% $602.90
2026-10-07 Barclays — $600 $625 +25 +3.7% $602.90
2026-09-30 UBS — $452 $673 +221 +8.2% $622.11
2026-07-24 RBC Capital Ryan Halsted $484 $692 +208 +15.0% $601.73
2026-07-24 Mizuho Securities — $586 $665 +79 +9.8% $605.82
2026-07-24 BMO Capital — $400 $600 +200 -1.0% $605.82
2026-07-24 Robert W. Baird — $547 $624 +77 +3.0% $605.82
2026-07-23 Barclays Luke Sergott $450 $600 +150 -1.0% $605.82
2026-07-23 Leerink Partners — $330 $620 +290 +2.3% $605.82
2026-07-23 Deutsche Bank — Initiated $535 — -11.3% $603.00
2026-07-13 Mizuho Securities — $582 $586 +4 +8.9% $538.23
2026-07-08 Robert W. Baird Eric Coldwell $477 $547 +70 +0.1% $546.29
2026-07-07 Jefferies David Windley $560 $515 -45 -8.9% $565.09
2026-04-24 BMO Capital — $460 $400 -60 -0.7% $402.81
2026-04-24 RBC Capital Ryan Halsted Initiated $484 — +23.0% $393.42
2026-04-24 Robert W. Baird Eric Coldwell $564 $477 -87 +21.2% $393.42
2026-04-24 Barclays Luke Sergott $500 $450 -50 +14.4% $393.42
2026-03-06 Barclays Luke Sergott $525 $500 -25 +6.8% $468.36
2026-02-13 Jefferies David Windley $345 $560 +215 +34.6% $416.04
2026-02-11 Truist Financial — $555 $539 -16 +25.0% $431.17
2026-02-11 Mizuho Securities — $660 $582 -78 +30.5% $446.05
2026-02-11 BMO Capital — Initiated $460 — +3.1% $446.05
2026-02-10 Robert W. Baird — $613 $564 -49 +23.8% $455.64
2026-01-09 Mizuho Securities — $655 $660 +5 +10.0% $600.02
2025-12-15 Barclays Luke Sergott $425 $525 +100 -5.9% $557.78
2025-10-27 Truist Financial Jailendra Singh $415 $555 +140 -8.3% $605.20
2025-10-24 Robert W. Baird — $349 $613 +264 +2.7% $596.61
2025-10-24 Mizuho Securities — $575 $655 +80 +9.6% $597.45
2025-10-17 Mizuho Securities — $435 $575 +140 +10.3% $521.21
2025-10-02 Barclays — Initiated $425 — -21.9% $543.90
2025-03-24 Leerink Partners Michael Cherny Initiated $330 — -0.2% $330.59
2024-10-22 Robert W. Baird Eric Coldwell $469 $349 -120 +6.9% $326.54
2024-09-25 Jefferies David Windley $450 $345 -105 -3.0% $355.82
2024-08-01 Truist Financial Jailendra Singh Initiated $415 — +8.5% $382.52
2024-07-08 Robert W. Baird Eric Coldwell $456 $469 +13 +16.1% $404.13
2024-06-13 Robert W. Baird Eric Coldwell Initiated $456 — +12.9% $403.74
2024-05-28 Mizuho Securities Ann Hynes Initiated $435 — +11.4% $390.55
2024-04-22 Jefferies David Windley Initiated $450 — +19.6% $376.26
2024-02-14 UBS John Sourbeer Initiated $452 — +14.6% $394.34

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

B+
Oct 27, 2026
DCF
4
ROE
5
ROA
5
D/E
2
P/E
2
P/B
1
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. MEDP receives an overall rating of B+. Strongest factors: DCF (4/5), ROE (5/5), ROA (5/5). Areas of concern: D/E (2/5), P/E (2/5), P/B (1/5).

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 80 Grade A+
Profitability
79
Balance Sheet
75
Earnings Quality
64
Growth
82
Value
32
Momentum
94
Safety
100
Cash Flow
79
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. MEDP scores highest in Safety (100/100) and lowest in Value (32/100). An overall grade of A+ places MEDP among the highest-quality companies in its peer group.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
7.94
Safe Zone
Piotroski F-Score
9/9
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Beneish M-Score
-2.78
Unlikely Manipulator
Ohlson O-Score
-6.70
Bankruptcy prob: 0.1%
Low Risk
Credit Rating
AA+
Score: 92.6/100
Trend: Stable
Earnings Quality
75/100
OCF/NI: 1.40x
Accruals: -10.1%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. MEDP scores 7.94, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. MEDP scores 9/9, signaling strong financial health across all three dimensions. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. MEDP's score of -2.78 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. MEDP's implied 0.1% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. MEDP receives an estimated rating of AA+ (score: 92.6/100), with a stable trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). MEDP's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
36.71x
PEG
1.45x
P/S
6.64x
P/B
32.19x
P/FCF
26.53x
P/OCF
24.49x
EV/EBITDA
26.65x
EV/Revenue
6.04x
EV/EBIT
27.84x
EV/FCF
25.69x
Earnings Yield
2.92%
FCF Yield
3.77%
Shareholder Yield
1.66%
Graham Number
$92.01
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 36.7x earnings, MEDP commands a growth premium. Graham's intrinsic value formula yields $92.01 per share, 636% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.826
NI / EBT
×
Interest Burden
1.018
EBT / EBIT
×
EBIT Margin
0.217
EBIT / Rev
×
Asset Turnover
1.400
Rev / Assets
×
Equity Multiplier
4.616
Assets / Equity
=
ROE
117.9%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. MEDP's ROE of 117.9% is driven by financial leverage (equity multiplier: 4.62x). Note: high leverage means ROE is amplified by debt rather than operational performance.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
15.00%
Fair P/E
38.50x
Intrinsic Value
$702.67
Price/Value
0.89x
Margin of Safety
11.17%
Premium
-11.17%
Assessment
Neutral
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with MEDP's realized 15.0% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. MEDP actually compounded EPS at 28.5% over three years; the model uses 15%, the highest rate it will extrapolate — of 4,457 company-quarters that grew faster than 200%, none sustained it over the following seven years. MEDP trades at a -11% premium to its adjusted intrinsic value of $702.67, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 38.5x compares to the current market P/E of 36.7x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$673.79
Median 1Y
$804.99
5th Pctile
$363.47
95th Pctile
$1784.02
Ann. Volatility
48.6%
Analyst Target
$678.33
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
August J. Troendle,
Chief Executive Officer Kevin M. Brady, Chief Financial Officer and Treasurer
$937,417 $— $11,443,766
Stephen P. Ewald,
General Counsel and Corporate Secretary
$710,417 $— $2,723,814
Susan E. Burwig,
Executive Vice President, Operations
$641,667 $— $2,396,370
Jesse J. Geiger,
President
$459,695 $— $1,646,197

CEO Pay Ratio

359:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $11,443,766
Avg Employee Cost (SGA/emp): $31,864
Employees: 6,200

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
6,200
+5.1% YoY
Revenue / Employee
$408,102
Rev: $2,530,234,000
Profit / Employee
$72,762
NI: $451,123,000
SGA / Employee
$31,864
Avg labor cost proxy

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
ROE 20.7% 27.3% 36.9% 36.3% 36.6% 54.0% 79.7% 66.6% 59.8% 61.3% 58.9% 54.1% 58.4% 65.8% 89.4% 73.7% 70.2% 77.3% 1.6% 1.2% 1.18%
ROA 11.9% 14.3% 15.0% 15.6% 16.3% 18.8% 19.7% 19.4% 18.8% 19.6% 20.4% 20.5% 21.5% 22.5% 24.0% 22.6% 22.1% 22.9% 27.1% 25.5% 25.54%
ROIC 28.7% 29.6% 32.8% 36.8% 44.2% 45.6% 49.4% 53.9% 62.3% 76.3% 84.9% 97.9% 1.2% 1.4% 1.5% 2.8% 2.1% 6.7% 6.4% 19.5% 19.54%
ROCE 18.1% 28.3% 54.2% 52.2% 50.6% 58.3% 56.9% 49.7% 46.3% 42.5% 41.4% 39.4% 44.9% 58.9% 1.4% 1.1% 85.1% 72.9% 94.6% 76.4% 76.39%
Gross Margin 28.5% 29.8% 28.2% 31.0% 29.4% 30.0% 27.0% 27.0% 27.4% 30.4% 29.1% 31.7% 33.2% 31.9% 29.8% 29.8% 29.0% 27.8% 28.5% 31.3% 31.27%
Operating Margin 17.8% 19.4% 17.2% 20.3% 19.4% 19.9% 17.0% 17.2% 17.5% 20.4% 19.9% 21.1% 23.4% 20.3% 20.9% 21.5% 21.6% 20.0% 20.8% 23.1% 23.12%
Net Margin 16.2% 18.5% 14.1% 17.2% 17.4% 16.8% 13.3% 14.3% 15.7% 20.1% 16.7% 18.1% 21.8% 20.5% 15.0% 16.8% 19.1% 17.5% 17.2% 19.2% 19.20%
EBITDA Margin 19.5% 20.9% 19.4% 23.3% 18.6% 21.2% 18.4% 18.6% 19.4% 21.7% 21.3% 22.5% 24.8% 21.6% 19.5% 22.7% 23.1% 21.9% 20.9% 24.8% 24.79%
FCF Margin 20.6% 18.2% 19.4% 20.8% 24.1% 24.6% 22.3% 21.2% 21.0% 24.1% 24.8% 25.9% 27.1% 25.1% 26.0% 29.8% 28.0% 27.5% 26.4% 23.5% 23.52%
OCF Margin 23.1% 20.8% 22.2% 23.4% 26.6% 27.0% 24.4% 23.2% 23.0% 25.8% 26.6% 27.7% 28.9% 27.0% 27.5% 30.2% 28.2% 27.6% 27.1% 25.5% 25.47%
ROE 3Y Avg snapshot only 92.49%
ROE 5Y Avg snapshot only 80.06%
ROA 3Y Avg snapshot only 21.58%
ROIC Economic snapshot only 74.37%
Cash ROA snapshot only 31.40%
Cash ROIC snapshot only 28.17%
CROIC snapshot only 26.01%
NOPAT Margin snapshot only 17.67%
Pretax Margin snapshot only 22.09%
R&D / Revenue snapshot only 0.00%
SGA / Revenue snapshot only 6.79%
SBC / Revenue snapshot only 0.79%
Valuation
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
P/E Ratio 45.17 29.77 24.10 22.36 28.07 23.53 28.23 28.15 34.49 41.39 38.89 29.29 26.30 22.83 22.63 35.28 36.06 30.21 30.99 34.20 36.711
P/S Ratio 7.19 4.90 3.92 3.69 4.72 3.87 4.53 4.32 5.17 6.59 6.51 5.17 5.04 4.41 4.24 6.48 6.43 5.19 5.47 6.24 6.642
P/B Ratio 8.62 9.83 17.80 14.49 17.82 17.41 19.39 16.33 17.45 19.26 17.31 12.15 12.88 16.01 54.93 52.02 35.44 23.24 35.11 30.28 32.195
P/FCF 34.94 26.89 20.18 17.76 19.61 15.72 20.31 20.36 24.59 27.32 26.28 20.00 18.59 17.57 16.33 21.71 22.95 18.85 20.77 26.53 26.526
P/OCF 31.19 23.58 17.63 15.73 17.75 14.33 18.60 18.59 22.51 25.56 24.48 18.64 17.47 16.33 15.42 21.48 22.81 18.81 20.24 24.49 24.492
EV/EBITDA 35.66 25.28 20.89 18.53 23.49 19.38 22.78 22.62 26.42 32.95 31.18 23.16 21.25 18.93 19.50 29.06 29.03 22.83 24.15 26.65 26.649
EV/Revenue 6.90 4.95 4.19 3.87 4.83 4.00 4.63 4.34 5.12 6.45 6.32 4.92 4.80 4.26 4.29 6.42 6.33 4.99 5.35 6.04 6.042
EV/EBIT 39.43 27.74 22.78 20.06 25.38 20.88 24.53 24.42 28.47 35.48 33.46 24.77 22.64 20.14 20.12 29.89 29.79 23.39 25.29 27.84 27.838
EV/FCF 33.54 27.15 21.55 18.62 20.07 16.26 20.73 20.48 24.33 26.75 25.53 19.01 17.68 16.99 16.51 21.51 22.61 18.13 20.28 25.69 25.688
Earnings Yield 2.2% 3.4% 4.1% 4.5% 3.6% 4.2% 3.5% 3.6% 2.9% 2.4% 2.6% 3.4% 3.8% 4.4% 4.4% 2.8% 2.8% 3.3% 3.2% 2.9% 2.92%
FCF Yield 2.9% 3.7% 5.0% 5.6% 5.1% 6.4% 4.9% 4.9% 4.1% 3.7% 3.8% 5.0% 5.4% 5.7% 6.1% 4.6% 4.4% 5.3% 4.8% 3.8% 3.77%
PEG Ratio snapshot only 1.455
EV/OCF snapshot only 23.719
EV/Gross Profit snapshot only 20.733
Acquirers Multiple snapshot only 28.247
Shareholder Yield snapshot only 1.66%
Graham Number snapshot only $92.01
Leverage & Solvency
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
Current Ratio 1.24 0.61 0.37 0.41 0.42 0.42 0.44 0.53 0.64 0.78 0.88 0.99 0.93 0.73 0.43 0.57 0.74 0.85 0.73 0.83 0.832
Quick Ratio 1.24 0.61 0.37 0.41 0.42 0.42 0.44 0.53 0.64 0.78 0.88 0.99 0.93 0.73 0.43 0.57 0.74 0.85 0.73 0.83 0.832
Debt/Equity 0.14 0.23 1.36 0.80 0.49 0.74 0.50 0.30 0.25 0.20 0.17 0.15 0.18 0.21 0.87 0.49 0.55 0.20 0.33 0.25 0.250
Net Debt/Equity -0.35 0.10 1.21 0.71 0.42 0.61 0.40 0.10 -0.18 -0.40 -0.50 -0.60 -0.63 -0.53 0.60 -0.48 -0.54 -0.89 -0.83 -0.96 -0.956
Debt/Assets 0.08 0.11 0.29 0.21 0.14 0.18 0.14 0.10 0.09 0.08 0.07 0.06 0.07 0.07 0.10 0.08 0.13 0.06 0.07 0.06 0.063
Debt/EBITDA 0.59 0.60 1.49 0.97 0.63 0.80 0.57 0.42 0.39 0.35 0.32 0.29 0.31 0.26 0.31 0.28 0.45 0.21 0.23 0.23 0.227
Net Debt/EBITDA -1.49 0.25 1.33 0.86 0.54 0.65 0.46 0.14 -0.28 -0.70 -0.92 -1.20 -1.09 -0.65 0.21 -0.27 -0.45 -0.91 -0.58 -0.87 -0.869
Interest Coverage 1904.23 2379.65 386.25 123.01 93.83 78.44 68.02 100.32 145.38 242.62 3653.76 — — — — — — — — — —
Equity Multiplier 1.74 2.22 4.64 3.80 3.50 4.02 3.60 3.16 2.96 2.67 2.51 2.36 2.54 3.20 9.12 5.97 4.30 3.56 4.74 3.94 3.936
Cash Ratio snapshot only 0.471
Cash to Debt snapshot only 4.830
FCF to Debt snapshot only 4.571
Defensive Interval snapshot only 1912.6 days
Efficiency & Turnover
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
Asset Turnover 0.75 0.87 0.92 0.95 0.97 1.14 1.23 1.27 1.25 1.23 1.22 1.16 1.12 1.17 1.28 1.23 1.24 1.33 1.53 1.40 1.400
Inventory Turnover — — — — — — — — — — — — — — — — — — — — —
Receivables Turnover 7.93 7.65 8.30 7.79 8.04 7.79 7.86 7.66 7.71 8.07 7.58 7.37 7.44 7.67 6.72 6.96 7.30 8.09 7.02 6.92 6.917
Payables Turnover 31.18 36.98 35.05 36.39 34.98 35.15 37.93 44.64 41.93 45.95 47.58 52.73 45.12 34.46 43.19 61.63 58.34 39.68 49.06 57.30 57.296
DSO 46 48 44 47 45 47 46 48 47 45 48 50 49 48 54 52 50 45 52 53 52.8 days
DIO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 days
DPO 12 10 10 10 10 10 10 8 9 8 8 7 8 11 8 6 6 9 7 6 6.4 days
Cash Conversion Cycle 34 38 34 37 35 36 37 39 39 37 40 43 41 37 46 47 44 36 45 46 46.4 days
Fixed Asset Turnover snapshot only 8.665
Cash Velocity snapshot only 4.024
Capital Intensity snapshot only 0.811
Growth (YoY)
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
Revenue 23.4% 27.1% 25.1% 25.7% 27.8% 28.8% 30.0% 29.6% 29.2% 25.6% 21.4% 16.2% 11.8% 9.9% 9.9% 13.9% 20.0% 24.2% 24.7% 20.4% 20.35%
Net Income 25.1% 25.1% 19.2% 24.1% 34.9% 28.6% 28.4% 20.5% 15.3% 21.6% 26.5% 33.9% 43.0% 33.2% 23.1% 18.4% 11.6% 10.6% 17.5% 19.6% 19.59%
EPS 24.8% 29.9% 33.4% 24.1% 57.1% 45.4% 37.0% 22.3% 17.4% 22.2% 24.5% 32.5% 42.1% 36.7% 30.9% 27.9% 23.3% 19.1% 23.2% 25.2% 25.23%
FCF 3.4% -5.7% -2.5% 5.4% 49.4% 73.9% 49.4% 32.3% 13.0% 23.0% 34.7% 41.8% 44.2% 14.3% 15.3% 31.4% 23.8% 36.4% 26.5% -5.1% -5.11%
EBITDA 18.5% 19.3% 21.4% 29.7% 35.7% 35.8% 31.7% 19.2% 21.8% 19.0% 21.2% 28.5% 30.3% 26.4% 19.2% 18.4% 15.9% 20.7% 25.5% 23.6% 23.56%
Op. Income 18.9% 20.1% 21.7% 29.4% 40.3% 39.7% 36.8% 26.8% 20.9% 18.0% 19.6% 25.4% 32.7% 28.7% 25.2% 24.0% 19.7% 23.4% 22.2% 19.7% 19.74%
OCF Growth snapshot only 1.66%
Asset Growth snapshot only 31.35%
Equity Growth snapshot only 99.20%
Debt Growth snapshot only 1.44%
Shares Change snapshot only -4.50%
Growth (CAGR)
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
Revenue 3Y 17.5% 17.8% 17.8% 18.6% 19.2% 20.6% 23.8% 25.7% 26.8% 27.1% 25.4% 23.7% 22.7% 21.1% 20.2% 19.7% 20.1% 19.7% 18.5% 16.8% 16.80%
Revenue 5Y 39.5% 30.3% 24.6% 26.1% 27.3% 26.0% 24.6% 23.3% 21.8% 21.5% 20.9% 20.3% 19.6% 19.3% 20.4% 21.4% 22.3% 22.9% 22.0% 21.0% 21.02%
EPS 3Y 34.8% 38.1% 37.8% 41.7% 41.9% 40.2% 43.8% 37.7% 32.0% 32.1% 31.5% 26.2% 37.9% 34.4% 30.7% 27.5% 27.2% 25.8% 26.2% 28.5% 28.50%
EPS 5Y 1.1% 76.1% 61.6% 58.3% 48.8% 45.1% 43.0% 38.9% 35.2% 36.1% 34.9% 35.8% 36.7% 35.7% 37.1% 34.7% 32.2% 30.3% 29.7% 26.4% 26.37%
Net Income 3Y 35.4% 36.9% 33.1% 34.4% 34.7% 32.6% 36.0% 30.0% 24.8% 25.1% 24.6% 26.0% 30.5% 27.7% 26.0% 24.1% 22.5% 21.5% 22.3% 23.8% 23.76%
Net Income 5Y 1.1% 71.5% 55.5% 52.1% 44.4% 41.5% 38.8% 34.7% 31.0% 32.1% 30.8% 31.4% 32.1% 30.5% 31.4% 28.3% 25.4% 23.6% 22.9% 23.2% 23.17%
EBITDA 3Y 16.2% 17.9% 19.3% 24.2% 25.9% 27.3% 31.0% 26.9% 25.1% 24.5% 24.7% 25.7% 29.1% 26.9% 23.9% 22.0% 22.5% 22.0% 21.9% 23.4% 23.44%
EBITDA 5Y 37.8% 27.1% 21.0% 23.1% 22.0% 23.3% 23.3% 21.8% 21.0% 21.5% 22.1% 24.1% 26.0% 25.4% 26.6% 25.5% 24.2% 24.1% 23.7% 23.8% 23.81%
Gross Profit 3Y 15.0% 15.7% 16.6% 18.4% 20.7% 22.0% 25.3% 24.9% 23.5% 23.4% 23.1% 23.9% 26.0% 24.9% 23.7% 21.9% 20.7% 18.8% 17.8% 18.0% 18.00%
Gross Profit 5Y 30.1% 21.7% 16.6% 18.2% 19.9% 21.1% 21.0% 20.5% 19.5% 19.6% 19.8% 20.3% 21.7% 21.6% 23.2% 23.2% 22.2% 21.7% 20.9% 20.7% 20.69%
Op. Income 3Y 25.3% 26.3% 25.2% 28.3% 29.9% 30.0% 34.3% 30.1% 26.3% 25.6% 25.8% 27.2% 31.0% 28.5% 27.0% 25.4% 24.3% 23.2% 22.3% 23.0% 23.04%
Op. Income 5Y 50.8% 39.0% 32.2% 32.8% 33.9% 34.2% 33.2% 30.6% 27.2% 27.1% 26.3% 27.4% 28.6% 27.2% 29.4% 27.9% 26.2% 25.7% 25.0% 25.0% 25.02%
FCF 3Y 18.7% 13.2% 15.9% 19.2% 24.1% 25.2% 25.7% 27.8% 20.4% 26.4% 25.2% 25.5% 34.5% 34.7% 32.4% 35.1% 26.4% 24.2% 25.2% 20.9% 20.90%
FCF 5Y 30.0% 30.5% 23.6% 28.0% 32.8% 28.6% 26.2% 23.8% 23.1% 25.4% 25.7% 26.0% 25.5% 22.5% 25.3% 31.2% 25.5% 25.8% 23.4% 19.8% 19.76%
OCF 3Y 18.9% 14.7% 18.4% 20.5% 24.3% 24.8% 23.9% 25.3% 18.8% 23.8% 23.7% 24.5% 32.2% 32.1% 29.0% 30.2% 22.5% 20.6% 22.7% 20.5% 20.46%
OCF 5Y 29.9% 29.0% 23.2% 26.9% 31.8% 28.3% 25.2% 23.2% 22.6% 24.8% 25.6% 25.5% 24.7% 21.8% 23.4% 27.6% 22.5% 22.6% 21.4% 19.4% 19.40%
Assets 3Y 19.7% 10.1% 9.0% 7.4% 5.8% 7.1% 4.8% 4.7% 6.0% 7.4% 9.3% 9.7% 8.2% 12.2% 6.1% 9.7% 13.5% 15.1% 13.5% 15.7% 15.70%
Assets 5Y 11.1% 6.8% 6.4% 7.0% 7.3% 7.5% 7.8% 9.4% 11.3% 12.3% 13.6% 14.2% 12.9% 10.8% 5.2% 6.2% 7.3% 8.0% 7.0% 7.9% 7.86%
Equity 3Y 17.3% -0.9% -24.5% -20.3% -19.0% -21.5% -19.1% -15.9% -11.5% -7.9% -3.6% -0.6% -4.7% -0.6% -15.3% -5.7% 5.9% 19.9% 3.5% 7.5% 7.50%
Book Value 3Y 16.8% -0.1% -21.8% -16.0% -14.6% -17.0% -14.4% -10.9% -6.4% -2.7% 1.8% -0.5% 0.7% 4.6% -12.1% -3.1% 10.0% 24.1% 6.8% 11.6% 11.62%
Dividend 3Y — — — — — — — — — — — — — — — — — — — — —
Growth Quality
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
Revenue Stability 0.97 0.98 0.98 0.98 0.97 0.96 0.95 0.94 0.92 0.92 0.94 0.95 0.96 0.97 0.98 0.99 0.99 0.99 0.99 0.99 0.993
Earnings Stability 1.00 0.99 0.97 0.99 0.98 0.99 0.98 0.99 0.99 0.99 0.98 0.98 0.95 0.97 0.99 0.98 0.97 0.98 0.99 0.98 0.984
Margin Stability 0.84 0.84 0.84 0.84 0.84 0.90 0.93 0.96 0.96 0.96 0.98 0.98 0.96 0.95 0.95 0.96 0.96 0.95 0.96 0.96 0.965
Rev. Growth Consistency 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Earn. Growth Consistency 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
FCF Positive Streak 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Earnings Persistence 0.90 0.90 0.92 0.90 0.86 0.89 0.89 0.92 0.94 0.91 0.89 0.86 0.83 0.87 0.91 0.93 0.95 0.96 0.93 0.92 0.922
Earnings Smoothness 0.78 0.78 0.82 0.78 0.70 0.75 0.75 0.81 0.86 0.80 0.77 0.71 0.65 0.71 0.79 0.83 0.89 0.90 0.84 0.82 0.822
ROE Trend 0.03 0.16 0.56 0.47 0.45 0.48 0.21 0.15 0.09 -0.07 -0.27 -0.20 -0.08 0.10 1.86 0.98 0.48 0.19 -0.30 -0.06 -0.059
Gross Margin Trend -0.01 -0.01 -0.00 0.00 0.00 0.00 -0.00 -0.01 -0.01 -0.01 -0.01 0.01 0.02 0.03 0.03 0.02 0.01 -0.01 -0.01 -0.01 -0.013
FCF Margin Trend -0.02 -0.05 -0.04 -0.02 0.01 0.03 0.00 -0.02 -0.01 0.03 0.04 0.05 0.05 0.01 0.02 0.06 0.04 0.03 0.01 -0.04 -0.043
Sustainable Growth Rate 20.7% 27.3% 36.9% 36.3% 36.6% 54.0% 79.7% 66.6% 59.8% 61.3% 58.9% 54.1% 58.4% 65.8% 89.4% 73.7% 70.2% 77.3% 1.6% 1.2% 1.18%
Internal Growth Rate 13.5% 16.7% 17.7% 18.5% 19.5% 23.1% 24.6% 24.1% 23.1% 24.4% 25.7% 25.8% 27.4% 29.1% 31.5% 29.1% 28.4% 29.6% 37.2% 34.3% 34.29%
Cash Flow Quality
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
OCF/Net Income 1.45 1.26 1.37 1.42 1.58 1.64 1.52 1.51 1.53 1.62 1.59 1.57 1.51 1.40 1.47 1.64 1.58 1.61 1.53 1.40 1.396
FCF/OCF 0.89 0.88 0.87 0.89 0.90 0.91 0.92 0.91 0.92 0.94 0.93 0.93 0.94 0.93 0.94 0.99 0.99 1.00 0.97 0.92 0.923
FCF/Net Income snapshot only 1.289
OCF/EBITDA snapshot only 1.124
CapEx/Revenue 2.5% 2.6% 2.8% 2.7% 2.5% 2.4% 2.1% 2.0% 1.9% 1.7% 1.8% 1.9% 1.7% 1.9% 1.5% 0.3% 0.2% 0.1% 0.7% 2.0% 1.95%
CapEx/Depreciation snapshot only 2.017
Accruals Ratio -0.05 -0.04 -0.06 -0.07 -0.09 -0.12 -0.10 -0.10 -0.10 -0.12 -0.12 -0.12 -0.11 -0.09 -0.11 -0.15 -0.13 -0.14 -0.14 -0.10 -0.101
Sloan Accruals snapshot only 0.132
Cash Flow Adequacy snapshot only 13.046
Earnings Quality Score snapshot only 0.750
Dividends & Buybacks
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
FCF Payout Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Total Payout Ratio 34.1% 2.4% 3.9% 3.5% 3.5% 2.1% 71.2% 70.0% 50.9% 7.6% 0.0% 0.0% 42.0% 1.3% 2.6% 2.5% 2.0% 1.2% 60.9% 56.9% 56.92%
Div. Increase Streak — — — — — — — — — — — — — — — — — — — — —
Chowder Number — — — — — — — — — — — — — — — — — — — — —
Buyback Yield 0.8% 8.2% 16.0% 15.8% 12.3% 9.0% 2.5% 2.5% 1.5% 0.2% 0.0% 0.0% 1.6% 5.7% 11.4% 7.1% 5.6% 3.9% 2.0% 1.7% 1.66%
Net Buyback Yield 0.8% 8.2% 16.0% 15.8% 12.3% 9.0% 2.5% 2.5% 1.5% 0.2% 0.0% 0.0% 1.6% 5.7% 11.4% 7.1% 5.5% 3.7% 1.7% 1.4% 1.39%
Total Shareholder Return 0.8% 8.2% 16.0% 15.8% 12.3% 9.0% 2.5% 2.5% 1.5% 0.2% 0.0% 0.0% 1.6% 5.7% 11.4% 7.1% 5.5% 3.7% 1.7% 1.4% 1.39%
DuPont Factors
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
Tax Burden (NI/EBT) 0.90 0.91 0.88 0.86 0.87 0.85 0.85 0.86 0.84 0.86 0.86 0.84 0.85 0.87 0.84 0.83 0.83 0.81 0.82 0.83 0.826
Interest Burden (EBT/EBIT) 1.01 1.01 1.01 1.00 1.02 1.01 1.01 1.01 0.99 1.02 1.04 1.05 1.07 1.05 1.04 1.03 1.01 1.00 1.02 1.02 1.018
EBIT Margin 0.18 0.18 0.18 0.19 0.19 0.19 0.19 0.18 0.18 0.18 0.19 0.20 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.22 0.217
Asset Turnover 0.75 0.87 0.92 0.95 0.97 1.14 1.23 1.27 1.25 1.23 1.22 1.16 1.12 1.17 1.28 1.23 1.24 1.33 1.53 1.40 1.400
Equity Multiplier 1.73 1.91 2.45 2.33 2.25 2.88 4.04 3.43 3.18 3.13 2.88 2.64 2.71 2.92 3.73 3.27 3.17 3.38 5.99 4.62 4.616
Per Share
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
EPS (Diluted TTM) $4.82 $5.50 $6.21 $7.03 $7.57 $7.99 $8.51 $8.60 $8.89 $9.77 $10.59 $11.40 $12.63 $13.35 $13.87 $14.57 $15.58 $15.90 $17.09 $18.25 $18.25
Book Value/Share $25.25 $16.64 $8.41 $10.85 $11.92 $10.80 $12.39 $14.83 $17.56 $20.99 $23.80 $27.47 $25.79 $19.03 $5.71 $9.88 $15.85 $20.66 $15.09 $20.62 $20.94
Tangible Book/Share $6.60 $-2.69 $-12.43 $-10.89 $-9.69 $-10.97 $-9.76 $-7.17 $-4.38 $-0.82 $2.06 $5.74 $4.02 $-3.30 $-17.37 $-13.54 $-8.17 $-3.36 $-9.10 $-3.89 $-3.89
Revenue/Share $30.27 $33.37 $38.17 $42.61 $45.03 $48.61 $52.98 $56.09 $59.26 $61.34 $63.27 $64.54 $65.88 $69.13 $73.99 $79.38 $87.36 $92.48 $96.74 $100.04 $101.59
FCF/Share $6.23 $6.08 $7.42 $8.85 $10.83 $11.97 $11.83 $11.89 $12.47 $14.79 $15.67 $16.69 $17.88 $17.34 $19.22 $23.68 $24.47 $25.48 $25.50 $23.53 $23.89
OCF/Share $6.98 $6.94 $8.49 $9.99 $11.97 $13.12 $12.91 $13.02 $13.62 $15.81 $16.83 $17.91 $19.02 $18.66 $20.36 $23.94 $24.62 $25.52 $26.17 $25.48 $25.88
Cash/Share $12.22 $2.28 $1.26 $0.96 $0.87 $1.46 $1.24 $3.00 $7.71 $12.72 $15.92 $20.47 $20.91 $14.15 $1.54 $9.60 $17.16 $22.54 $17.48 $24.86 $25.24
EBITDA/Share $5.86 $6.54 $7.65 $8.90 $9.25 $10.04 $10.76 $10.77 $11.48 $12.01 $12.83 $13.70 $14.87 $15.56 $16.27 $17.53 $19.06 $20.23 $21.42 $22.68 $22.68
Debt/Share $3.47 $3.89 $11.42 $8.65 $5.83 $8.01 $6.16 $4.50 $4.47 $4.25 $4.11 $4.00 $4.67 $4.06 $4.97 $4.85 $8.65 $4.22 $5.01 $5.15 $5.15
Net Debt/Share $-8.75 $1.62 $10.15 $7.69 $4.95 $6.55 $4.92 $1.51 $-3.25 $-8.46 $-11.82 $-16.47 $-16.24 $-10.09 $3.43 $-4.76 $-8.51 $-18.31 $-12.47 $-19.71 $-19.71
Academic Models
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — 7.944
Altman Z-Prime snapshot only 11.379
Piotroski F-Score 7 6 7 7 7 7 8 8 8 9 8 7 7 8 7 6 6 8 8 9 9
Beneish M-Score -2.51 -2.28 -2.42 -2.51 -2.64 -2.86 -2.68 -2.65 -2.70 -2.91 -2.92 -3.00 -3.04 -2.88 -2.84 -2.98 -2.71 -2.72 -2.92 -2.78 -2.777
Ohlson O-Score snapshot only -6.699
Net-Net WC snapshot only $-16.66
EVA snapshot only $498858873.49
Credit
Metric Trend Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Current
Credit Rating snapshot only AA+
Credit Score 96.09 95.79 89.47 91.15 96.59 95.98 96.12 96.33 96.17 96.09 96.44 92.89 93.47 93.35 93.53 93.38 93.64 93.08 93.50 92.61 92.614
Credit Grade snapshot only 2
Credit Trend snapshot only -0.770
Implied Spread (bps) snapshot only 65.000
Industry Credit Rank snapshot only 86
Sector Credit Rank snapshot only 86

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms